In Stock, Ready to Ship!
Price range: $160.00 through $325.00 — or subscribe and save 20%
99% Pure | USA Made | Multi DoseCagrilintide is a powerful, long-acting analogue of the naturally secreted hormone amylin—co-released with insulin. Designed to probe appetite control, glycemic balance, and fat-metabolism in lab models, Cagrilintide slows gastric emptying, modulates satiety pathways, and drives body-fat reduction in rodent and primate studies. When paired with GLP-1 agonists like semaglutide or retatrutide, it delivers amplified metabolic effects. Each 10 mg vial is USA-manufactured, HPLC-tested to ≥99% purity, endotoxin-screened (<0.1 EU/mg), and shipped with a Certificate of Analysis—perfect for high-integrity obesity, diabetes, and NAFLD research.
Peptides are not ready to use. Must purchase BAC water for reconstitution.
Cagrilintide is a lab-engineered analogue of amylin—a 37-amino-acid peptide co-released with insulin that naturally suppresses appetite and slows digestion. By extending amylin’s half-life, Cagrilintide allows researchers to study sustained satiety signaling, gastric motility delay, and lipid-metabolism regulation in controlled in vitro and in vivo models without directly engaging insulin or glucagon receptors.
Researchers select Cagrilintide for its robust, long-acting action on key metabolic pathways. Its stable pharmacokinetics deliver sustained receptor engagement, yielding reproducible appetite-suppression and glycemic-control data across rodent and primate studies. Manufactured under ISO-certified, cGMP-like conditions, each vial undergoes rigorous HPLC purity testing and endotoxin screening—ensuring the consistency needed for obesity, diabetes, and NAFLD research protocols.
Unlike native amylin, which is rapidly degraded, Cagrilintide’s sequence modifications confer extended activity, making it uniquely suited for chronic metabolic studies. Its selective amylin-receptor agonism decouples satiety and gastric-motility effects from insulin pathways, allowing clear dissection of appetite and lipid-regulation mechanisms. Coupled with proven stability in both lyophilized and reconstituted forms, Cagrilintide stands out as a precision tool for multi-pathway metabolic research.
A six-month preclinical investigation demonstrates that a fixed-ratio combination of semaglutide and cagrilintide produces superior glycemic control and body-weight reduction compared to either agent alone in rodent and non-human primate assays pharmacytimes.com
An April 2025 review outlines cagrilintide’s receptor-binding kinetics, signaling pathways (including AMY1–3 activation), and metabolic effects—highlighting novel formulation strategies under study to extend peptide half-life and enhance metabolic-dysfunction protocols.
A rodent obesity/diabetes model compares KBP-based dual amylin–calcitonin receptor agonists to CagriSema (semaglutide + cagrilintide), showing comparable AMY3 activation but suggesting differentiated metabolic and weight-loss profiles across compounds.
Don't hestitate to contact us
End of Content.
